Annual report
4544.TEDINET S100TMPA
Period2023-04-01 → 2024-03-31
Filed2024-06-19
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥236.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥223.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥188.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥4.0bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥23.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.9bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥516m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥290.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥252.8bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥219.4bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥148.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥142.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥115.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥103.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥39.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥36.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥35.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥16.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥28.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥21.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥8.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-132.77 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.38 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9.06 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥306.32 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,506.5 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,635.26 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,463.33 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,020.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,809.18 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 49.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 23.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,295 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,437 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,444 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,897 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,968 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥23.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥24.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.1bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥15.0bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥40.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥11.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥13.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥12.4bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.2bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥9.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥12.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥5.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥115m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥27.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥178.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥182.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥173.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥167.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥161.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111.5bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥119.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥66.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥63.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥60.5bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥66.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥35.7bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥37.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥170.4 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥225.98 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.08 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.02 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥485.53 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥170.39 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥225.97 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥103.05 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.02 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥485.42 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥125 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥125 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥125 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥144 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,172.79 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.11 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,032.83 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,058.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,171.23 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 37.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.8% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 48.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 57,473,822 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,471,867 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,446,657 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,416,407 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 57,387,861 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 400 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 392 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 330 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 322 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥949m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥5.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥5.9bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥35.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥5.8bn |
| Clinical Lab Testing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥9.9bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥12.3bn |
| Clinical Lab Testing Businessreportable segment | employees | at 2024-03-31 | 2023 pure |
| Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥147.0bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥146.7bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥258m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2024-03-31 | ¥117.9bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥12.5bn |
| In Vitro Diagnostics Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥6.9bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| In Vitro Diagnostics Businessreportable segment | employees | at 2024-03-31 | 1103 pure |
| In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥67.5bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥61.9bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2024-03-31 | ¥124.6bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥12.9bn |
| Sterilization And Related Servicesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.3bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Sterilization And Related Servicesreportable segment | employees | at 2024-03-31 | 1006 pure |
| Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥28.3bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥28.3bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2024-03-31 | ¥13.1bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.3bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥18.2bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥18.9bn |
| —segment total | employees | at 2024-03-31 | 4132 pure |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥242.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥236.9bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.9bn |
| —segment total | segment assets | at 2024-03-31 | ¥255.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥23.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥4.5bn |
| Clinical Lab Testing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Clinical Lab Testing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥12.0bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥163.4bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥163.1bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥293m |
| Clinical Lab Testing Businessreportable segment | segment assets | at 2023-03-31 | ¥131.1bn |
| Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥279m |
| In Vitro Diagnostics Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.4bn |
| In Vitro Diagnostics Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4.2bn |
| In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥77.7bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥70.1bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.6bn |
| In Vitro Diagnostics Businessreportable segment | segment assets | at 2023-03-31 | ¥129.2bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥26.5bn |
| Sterilization And Related Servicesreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Sterilization And Related Servicesreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥27.8bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥17m |
| Sterilization And Related Servicesreportable segment | segment assets | at 2023-03-31 | ¥13.8bn |
| Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥21.4bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥17.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥268.8bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥260.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| —segment total | segment assets | at 2023-03-31 | ¥274.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥27.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,846
| Item | Context | Value | Unit |
|---|---|---|---|
| Official title or position information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000IshikawaGokiMember | Original text (Japanese)執行役IVD担当 | |
| Name information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000IshikawaGokiMember | Original text (Japanese)石川 剛生 | |
| Date of birth information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000IshikawaGokiMember | 1976-11-18 | |
| Career summary information about executive directors (text) | FilingDateInstant_jpcrp030000-asr_E00967-000IshikawaGokiMember | Text · Plus | |
| Term of office information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000IshikawaGokiMember | Original text (Japanese)（注） | |
| Official title or position information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000MatsumotoMakotoMember | Original text (Japanese)執行役LTS担当 | |
| Name information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000MatsumotoMakotoMember | Original text (Japanese)松本 誠 | |
| Date of birth information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000MatsumotoMakotoMember | 1968-07-07 | |
| Career summary information about executive directors (text) | FilingDateInstant_jpcrp030000-asr_E00967-000MatsumotoMakotoMember | Text · Plus | |
| Term of office information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000MatsumotoMakotoMember | Original text (Japanese)（注） | |
| Official title or position information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000OmiKazuyaMember | Original text (Japanese)執行役 兼 CTO | |
| Name information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000OmiKazuyaMember | Original text (Japanese)小見 和也 | |
| Date of birth information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000OmiKazuyaMember | 1979-02-28 | |
| Career summary information about executive directors (text) | FilingDateInstant_jpcrp030000-asr_E00967-000OmiKazuyaMember | Text · Plus | |
| Term of office information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000OmiKazuyaMember | Original text (Japanese)（注） | |
| Official title or position information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000ShimizuToshihikoMember | Original text (Japanese)執行役 兼 CIO | |
| Name information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000ShimizuToshihikoMember | Original text (Japanese)清水 俊彦 | |
| Date of birth information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000ShimizuToshihikoMember | 1955-08-24 | |
| Career summary information about executive directors (text) | FilingDateInstant_jpcrp030000-asr_E00967-000ShimizuToshihikoMember | Text · Plus | |
| Term of office information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000ShimizuToshihikoMember | Original text (Japanese)（注） | |
| Official title or position information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000HasegawaTadashiMember | Original text (Japanese)執行役社長特命担当 | |
| Name information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000HasegawaTadashiMember | Original text (Japanese)長谷川 正 | |
| Date of birth information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000HasegawaTadashiMember | 1970-01-28 | |
| Career summary information about executive directors (text) | FilingDateInstant_jpcrp030000-asr_E00967-000HasegawaTadashiMember | Text · Plus | |
| Term of office information about executive directors | FilingDateInstant_jpcrp030000-asr_E00967-000HasegawaTadashiMember | Original text (Japanese)（注） | |
| Footnotes executive officers (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱ファルコホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)当社グループの取引先であり、定量的な基準を満たしていることから、継続して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)㈱メンタルヘルステクノロジーズ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)㈱ビー・エム・エル | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of group company holding second largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)株式会社エスアールエル | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)札幌臨床検査センター㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |